Clinical Trial

Comprehensive Rehabilitation Programme in People With Multiple Sclerosis: The RECONNECT-MS Study

Study acronym: RECONNECT-MS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if a comprehensive rehabilitation programme can improve physical function, reduce fatigue, and raise quality of life in adults aged 18-65 with multiple sclerosis (MS). The study will also look at whether the programme leads to changes in brain function using magnetic resonance imaging (MRI). The main questions it aims to answer are: * Does the programme lower the overall impact of MS on daily life? * Does the programme improve walking, balance, and hand function? * Does the programme reduce the impact of fatigue? * Are there changes in brain connections after the programme? Each participant serves as their own comparison. They are tested 3 times: 2 months before the programme starts (T0), right before it starts (T1), and after 2 months of intensive treatment (T2). The period between T0 and T1, when no treatment is given, shows each person's natural changes over time. Participants will: * Attend individual physiotherapy twice a week for 2 months, then 3 follow-up sessions over the next month * Take part in 3 group movement-awareness sessions * Take part in 3 group psychotherapy sessions focused on stress management and relaxation * Receive written nutritional guidance for autoimmune conditions Tests include physical assessments, questionnaires about fatigue and quality of life, tremor measurement, and brain MRI scans. The results may help improve rehabilitation care for people with MS and support their ability to stay active in everyday and working life.
Trial Details
NCT Number NCT07666958
Lead Sponsor Charles University, Czech Republic
Collaborators: Institute for Clinical and Experimental Medicine, Faculty Hospital Kralovske Vinohrady, Czech Ministry of Education
Conditions Multiple Sclerosis
Enrollment 45 participants
Start Date 2026-07-01
Primary Completion 2028-02-28 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-24